Archives
-
Notch1–YY1–ICAM1 Axis in HCC Immunotherapy
2026-09-02
The reference study identifies the Notch1–YY1–ICAM1 pathway as a molecular determinant of immunotherapy response in hepatocellular carcinoma (HCC). Its data connect pathway disruption with stronger CD8+ T-cell cytotoxicity and granzyme-driven pyroptosis, supporting downstream targeting of YY1 as a potentially safer complement to immune checkpoint blockade.
-
ASB3 Targets MAVS to Suppress Antiviral Immunity
2026-09-02
The reference study identifies ASB3 as an E3 ubiquitin ligase that weakens antiviral innate immunity by directing K48-linked ubiquitination and proteasomal degradation of MAVS. Its gain-of-function, loss-of-function, infection, and animal experiments connect ASB3 activity to reduced interferon signaling and greater susceptibility to influenza A virus, providing a mechanistic framework for studying host regulation of RIG-I-like receptor pathways.
-
N1-Methylpseudouridine for mRNA Workflows
2026-09-01
N1-Methylpseudouridine helps researchers build higher-output mRNA assays while managing innate immune activation and translational shutdown. This guide translates the NPC1 rescue study into practical design, dosing, controls, and troubleshooting choices for reporter and disease-relevant workflows.
-
Rex-Based NADH/NAD+ Biosensor for Bacteria
2026-09-01
Liu, Landick, and Raman developed a genetically encoded, ratiometric NADH/NAD+ biosensor by coupling the redox-responsive bacterial transcription factor Rex to an engineered promoter. The system enabled noninvasive measurements, revealed substantial redox changes in respiratory-chain mutants, and supported enrichment of rare high-NADH cells in pooled screens.
-
Angiotensin 1/2 (1-6): Assay Design Guide
2026-08-31
Angiotensin 1/2 (1-6) is a sequence-defined hexapeptide for RAS, cardiovascular, renal, and receptor-binding research. This guide connects peptide identity, assay controls, solubility, and recent spike–AXL findings to help researchers design more interpretable experiments.
-
RCN2 Drives ESCC Metastasis and Cisplatin Resistance
2026-08-31
The reference study identifies RCN2 as a driver of esophageal squamous cell carcinoma metastasis and cisplatin resistance through UBR5-dependent ubiquitination and degradation of PPP2CA. Its integrated molecular, cellular, and animal experiments define an RCN2–PPP2CA–PI3K-AKT axis that may help explain treatment failure and guide biomarker-oriented cancer research.
-
Deep Learning for iPSC-CM Cardiotoxicity Screening
2026-08-30
Grafton et al. combined human induced pluripotent stem cell-derived cardiomyocytes with high-content imaging and deep learning to identify cardiotoxic phenotypes across chemically diverse libraries. The study shows how a single computational score can support earlier, target-agnostic toxicity triage while also clarifying the limitations of translating image-based cellular signals into clinical risk.
-
N1-Methyl-Pseudouridine-5'-Triphosphate Guide
2026-08-29
This scenario-based guide explains how N1-Methyl-Pseudouridine-5'-Triphosphate, SKU B8049, can support more interpretable RNA-expression experiments linked to cell viability, proliferation, and cytotoxicity assays. It covers transcript design, controls, handling, data interpretation, and practical vendor-selection criteria without overstating evidence.
-
EZ Cap™ EPO mRNA for Translational Research
2026-08-28
EZ Cap™ EPO mRNA combines Cap 1 capping, pseudouridine, and a poly(A) tail for efficient human EPO expression in mammalian research models. This practical guide connects erythropoiesis assays with targeted nanoparticle workflows for neurorepair, while providing quantitative setup and troubleshooting guidance.
-
N1-Methylpseudouridine in Cell Assays
2026-08-28
Learn how N1-Methylpseudouridine, SKU B8340, can support more interpretable cell viability, proliferation, and cytotoxicity workflows by improving mRNA translation while helping limit innate immune confounding. The article provides scenario-based guidance on controls, formulation, storage, interpretation, and vendor selection.
-
2'-O-Methyladenosine: RNA and Purine Research
2026-08-27
2'-O-Methyladenosine is a methylated adenosine nucleoside used to investigate RNA modification biology, purine metabolism, and nucleoside transport. Stable-isotope UHPLC–MS/MS provides a sensitive framework for measuring related methylated purine nucleosides in cultured cells, while product-level handling data support controlled in-vitro use.
-
Nanoparticle mRNA Delivery to Reverse Trastuzumab Resistance
2026-08-27
Dong and colleagues developed a tumor-microenvironment-responsive nanoparticle system for systemic delivery of PTEN mRNA, aiming to restore a suppressed signaling brake in trastuzumab-resistant HER2-positive breast cancer. The study links pH-triggered nanoparticle uptake and PTEN expression with PI3K/Akt signaling pathway inhibition, reversal of resistance, and reduced tumor progression in preclinical models.
-
Accurate Quantification of Methylated Purine Nucleosides
2026-08-26
Zhang, Zhang, and Wang developed a stable isotope-diluted UHPLC–ESI-MS/MS method that simultaneously measures 12 purine ribonucleosides, including 10 methylated species. Ammonium bicarbonate-assisted ionization, isomer-resolved chromatography, and methanol–SPE cleanup improved sensitivity and enabled intracellular quantification in a cellular matrix.
-
LNP–MOMP mRNA Vaccine Protects Against C. psittaci
2026-08-26
Wang et al. developed a lipid nanoparticle-delivered, non-replicating mRNA vaccine encoding the major outer membrane protein of Chlamydia psittaci and evaluated its expression, immunogenicity, and protective activity in BALB/c mice. The study links MOMP expression with reduced pulmonary bacterial burden, shedding, and inflammatory cytokines, while also defining practical checkpoints for preclinical mRNA vaccine development.
-
Self-Amplifying RNA Influenza Vaccines: Dose Sparing
2026-08-25
This study shows that self-amplifying RNA can overcome the weak influenza B immunogenicity observed with conventional mRNA vaccination while maintaining strong dose-sparing performance against influenza A. Its head-to-head comparison of RNA platforms highlights how vaccine architecture, antigen design, and response durability can shape protection across viral subtypes.